31st Aug 2021 07:00
31 August 2021
Diaceutics PLC
("Diaceutics" or the "Group" or the "Company")
Investor Presentation
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, today announces that Peter Keeling, CEO, and Philip White, CFO, will provide a live presentation relating to the Company's Interim results for the six months ending 30 June 2021 via the Investor Meet Company platform on 15 September 2021 at 3:30pm.
The presentation is open to all existing and potential shareholders and registration can be completed via the following link:
https://www.investormeetcompany.com/diaceutics-plc/register-investor
Questions should be submitted by 9am on 14 September 2021 through the Investor Meet Company dashboard or at any time during the live presentation.
Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.
Enquiries:
Diaceutics PLC | |
Philip White, Chief Financial Officer | Via Alma PR |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison | |
Stewart Wallace | |
Nick Adams | |
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde | |
Robyn Fisher | |
Kieran Breheny Matthew Young |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Related Shares:
Diaceutics